To Nullify Modifications Made by the Food and Drug Administration on January 3, 2023, to the Risk Evaluation and Mitigation Strategy Under Section 505-1 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355-1) for Mifepristone, and for Other Purposes.

H.R. 5850 (118th Congress)